DZ2729A1 - Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant. - Google Patents

Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant.

Info

Publication number: DZ2729A1
Authority: DZ; Algeria
Prior art keywords: nhe; preparation; pharmaceutical compositions; compositions containing; new inhibitors
Prior art date: 1998-02-27

Application number

DZ990032A

Other languages

English (en)

French (fr)

Inventor

Ernest S Hamanaka

Guzman Perez Angel

Roger B Ruggeri

Ronald T Wester

Christian J Mularski

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-27

Filing date

1999-02-24

Publication date

2005-03-01

1999-02-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-03-01 Application granted granted Critical

2005-03-01 Publication of DZ2729A1 publication Critical patent/DZ2729A1/xx

Links

150000001875 compounds Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)

DZ990032A 1998-02-27 1999-02-24 Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant. DZ2729A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US7636298P	1998-02-27	1998-02-27

Publications (1)

Publication Number	Publication Date
DZ2729A1 true DZ2729A1 (fr)	2005-03-01

Family

ID=22131525

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990032A DZ2729A1 (fr)	1998-02-27	1999-02-24	Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant.

Country Status (39)

Country	Link
US (2)	US6492401B1 (id)
EP (2)	EP1056729B1 (id)
JP (2)	JP2002504546A (id)
KR (4)	KR100407903B1 (id)
CN (1)	CN1289326A (id)
AP (1)	AP9901478A0 (id)
AR (1)	AR015526A1 (id)
AT (1)	ATE286034T1 (id)
AU (1)	AU739403B2 (id)
BG (1)	BG104803A (id)
BR (1)	BR9908332A (id)
CA (1)	CA2321642A1 (id)
CO (1)	CO4980897A1 (id)
DE (1)	DE69922930T2 (id)
DK (1)	DK1056729T3 (id)
DZ (1)	DZ2729A1 (id)
EA (1)	EA003603B1 (id)
ES (1)	ES2237080T3 (id)
GT (1)	GT199900022A (id)
HR (2)	HRP20010666A2 (id)
HU (1)	HUP0204418A3 (id)
ID (1)	ID25505A (id)
IL (1)	IL136588A0 (id)
IS (1)	IS5548A (id)
NO (1)	NO20004192D0 (id)
NZ (1)	NZ504769A (id)
OA (1)	OA11450A (id)
PA (1)	PA8468401A1 (id)
PE (1)	PE20000334A1 (id)
PL (1)	PL342444A1 (id)
PT (1)	PT1056729E (id)
SI (1)	SI1056729T1 (id)
SK (1)	SK12342000A3 (id)
TN (1)	TNSN99028A1 (id)
TR (1)	TR200002480T2 (id)
TW (1)	TWI226329B (id)
WO (1)	WO1999043663A1 (id)
YU (1)	YU46200A (id)
ZA (1)	ZA991578B (id)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU46200A (sh) *	1998-02-27	2003-02-28	Pfizer Products Inc.	N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije
FR2795726A1 (fr) *	1999-06-30	2001-01-05	Aventis Cropscience Sa	Nouveaux pyrazoles fongicides
UA72002C2 (en) *	1999-10-29	2005-01-17	Pfizer Prod Inc	Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage
US6441176B1 (en)	1999-10-29	2002-08-27	Pfizer Inc.	Method for preparing sodium-hydrogen exchanger type 1 inhibitor
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es)	2000-01-21	2003-12-11	Inc Agouron Pharmaceuticals	Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6570013B2 (en)	2000-02-16	2003-05-27	Pfizer Inc	Salts of zopolrestat
US6555569B2 (en) *	2000-03-07	2003-04-29	Pfizer Inc.	Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
BR0110302A (pt)	2000-04-18	2003-01-14	Agouron Pharma	Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US6852733B2 (en) *	2000-04-28	2005-02-08	Pfizer Inc.	Sodium-hydrogen exchanger type 1 inhibitor
BR0110268A (pt) *	2000-04-28	2003-12-30	Pfizer Prod Inc	Inibidores de permutadores sódio-hidrogênio do tipo 1(nhe-1)
IL144507A0 (en) *	2000-07-31	2002-05-23	Pfizer Prod Inc	Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002044133A1 (en) *	2000-11-28	2002-06-06	Pfizer Products Inc.	Preparation of sodium-hydrogen exchanger type-1 inhibitors
IL147696A0 (en) *	2001-01-25	2002-08-14	Pfizer Prod Inc	Combination therapy
US6423705B1 (en)	2001-01-25	2002-07-23	Pfizer Inc.	Combination therapy
EP1355899A1 (en) *	2001-01-31	2003-10-29	Pfizer Products Inc.	Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
WO2002098429A1 (en) *	2001-06-07	2002-12-12	Pfizer Products Inc.	Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
AU2002352148A1 (en) *	2001-06-29	2003-03-03	Abbott Gmnh & Co. Kg	Bis-aryl thiazole derivatives
WO2003039528A1 (en) *	2001-11-02	2003-05-15	Aventis Pharmaceuticals Inc.	Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
CA2469305A1 (en)	2001-12-19	2003-06-26	Frank Robert Busch	Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
CA2472342A1 (en) *	2002-01-30	2003-08-07	Pfizer Products Inc.	Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
WO2003092694A1 (en) *	2002-05-02	2003-11-13	Pfizer Products Inc.	Treatment of diabetes and diabetic complications with nhe-1 inhibitors
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
FR2840302B1 (fr) *	2002-06-03	2004-07-16	Aventis Pharma Sa	Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842525B1 (fr) *	2002-07-16	2005-05-13	Aventis Pharma Sa	Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842526B1 (fr) *	2002-07-16	2007-07-13	Aventis Pharma Sa	Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
FR2842524B1 (fr) *	2002-07-16	2005-04-22	Aventis Pharma Sa	Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
WO2004050610A2 (en)	2002-12-04	2004-06-17	Gene Logic Inc.	Modulators of melanocortin receptor
ZA200505734B (en) *	2003-02-07	2006-12-27	Daiichi Seiyaku Co	Pyrazole Derivative
US7317109B2 (en)	2003-11-12	2008-01-08	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1689757B1 (en)	2003-11-12	2014-08-27	Phenomix Corporation	Heterocyclic boronic acid compounds
US7576121B2 (en)	2003-11-12	2009-08-18	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200526641A (en) *	2003-12-26	2005-08-16	Daiichi Seiyaku Co	Amidopyrazole derivatives
WO2005079803A1 (en) *	2004-02-13	2005-09-01	Pfizer Products, Inc.	Compounds for treatment of cardiovascular diseases
CA2573848A1 (en)	2004-07-12	2006-02-16	Phenomix Corporation	Constrained cyano compounds
US7223786B2 (en)	2004-11-15	2007-05-29	Bristol-Myers Squibb Company	2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en)	2004-11-15	2006-05-26	Bristol-Myers Squibb Company	2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en)	2004-11-15	2006-05-26	Bristol-Myers Squibb Company	2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en)	2004-11-15	2006-05-18	Bristol-Myers Squibb Company	2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
SI1853296T1 (sl) *	2005-01-10	2012-10-30	Debiopharm Sa	Uporaba cikličnega undekapeptida za pripravo zdravila za dajanje med miokardnimi ishemičnimi dogodki
EP2527337A1 (en)	2005-04-14	2012-11-28	Bristol-Myers Squibb Company	Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en)	2005-05-25	2010-11-02	Forest Laboratories Holdings Limited (BM)	Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2008005910A2 (en)	2006-07-06	2008-01-10	Bristol-Myers Squibb Company	Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en)	2006-08-24	2010-06-01	Bristol-Myers Squibb Company	Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008130951A1 (en)	2007-04-17	2008-10-30	Bristol-Myers Squibb Company	Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
CN101808995A (zh)	2007-07-27	2010-08-18	百时美施贵宝公司	新颖的葡糖激酶激活剂及其使用方法
US8759345B2 (en) *	2008-04-28	2014-06-24	Janssen Pharmaceutica Nv	Benzoimidazoles as prolyl hydroxylase inhibitors
US10517839B2 (en)	2008-06-09	2019-12-31	Cornell University	Mast cell inhibition in diseases of the retina and vitreous
MX2011005221A (es) *	2008-11-21	2011-08-03	Raqualia Pharma Inc	Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b.
WO2010094090A2 (en) *	2009-02-18	2010-08-26	Katholleke Universiteit Leuven	Synucleinopathies
WO2011130459A1 (en)	2010-04-14	2011-10-20	Bristol-Myers Squibb Company	Novel glucokinase activators and methods of using same
CN102408385B (zh) *	2011-06-20	2014-06-18	雅本化学股份有限公司	一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) *	2011-07-27	2014-05-07	雅本化学股份有限公司	2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
US9226505B2 (en)	2011-09-23	2016-01-05	Bayer Intellectual Property Gmbh	4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives as agents against abiotic plant stress
ES2818977T3 (es)	2011-10-25	2021-04-14	Janssen Pharmaceutica Nv	Método para obtener cristales de sal de meglumina de ácido 1-(5,6-dicloro-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico
EP2819675A4 (en)	2012-02-27	2015-07-22	Essentialis Inc	SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
MX383577B (es) *	2015-08-06	2025-03-14	Ube Industries	Derivados sustituidos de guanidina.
WO2017057695A1 (ja) *	2015-09-30	2017-04-06	東レ株式会社	ジフェニルピラゾール誘導体及びその医薬用途
PL3395801T3 (pl) *	2015-12-16	2021-10-18	Nippon Soda Co., Ltd.	Związek aryloazolowy i środek do zwalczania szkodników
US10344002B2 (en)	2016-09-26	2019-07-09	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
CN108017584B (zh) *	2017-06-20	2021-03-23	南开大学	A3腺苷受体的小分子拮抗剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2104931B1 (id) *	1970-09-08	1975-01-10	Ferlux
CA2121391A1 (en)	1993-04-28	1994-10-29	Atsuyuki Kojima	Indoloylguanidine derivatives
IL109570A0 (en)	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US5852046A (en)	1993-08-03	1998-12-22	Hoechst Aktiengesellschaft	Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
EP0639573A1 (de) *	1993-08-03	1995-02-22	Hoechst Aktiengesellschaft	Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
DE4412334A1 (de)	1994-04-11	1995-10-19	Hoechst Ag	Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2160600A1 (en)	1994-10-18	1996-04-19	Masahumi Kitano	Indoloylguanidine derivatives
CA2195697A1 (en)	1996-02-02	1997-08-03	Masahumi Kitano	Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
JPH09291076A (ja)	1996-04-24	1997-11-11	Sumitomo Pharmaceut Co Ltd	置換グアニジン誘導体およびその製法
AR009435A1 (es) *	1996-12-16	2000-04-12	Yamanouchi Pharma Co Ltd	Derivado de guanaidina n-[carbonil(heteroaril-substituida de 5 miembros)], un inhibidor del intercambiador de na+/h+ que comprende dicho derivado y usosen la fabricacion de medicamentos.
YU46200A (sh) *	1998-02-27	2003-02-28	Pfizer Products Inc.	N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije

1999
- 1999-02-05 YU YU46200A patent/YU46200A/sh unknown
- 1999-02-05 DE DE69922930T patent/DE69922930T2/de not_active Expired - Fee Related
- 1999-02-05 HR HR20010666A patent/HRP20010666A2/hr not_active Application Discontinuation
- 1999-02-05 DK DK99901083T patent/DK1056729T3/da active
- 1999-02-05 NZ NZ504769A patent/NZ504769A/en unknown
- 1999-02-05 IL IL13658899A patent/IL136588A0/xx unknown
- 1999-02-05 AT AT99901083T patent/ATE286034T1/de not_active IP Right Cessation
- 1999-02-05 PL PL99342444A patent/PL342444A1/xx not_active Application Discontinuation
- 1999-02-05 EP EP99901083A patent/EP1056729B1/en not_active Expired - Lifetime
- 1999-02-05 WO PCT/IB1999/000206 patent/WO1999043663A1/en not_active Ceased
- 1999-02-05 KR KR10-2002-7017553A patent/KR100407903B1/ko not_active Expired - Fee Related
- 1999-02-05 PT PT99901083T patent/PT1056729E/pt unknown
- 1999-02-05 ID IDW20001633A patent/ID25505A/id unknown
- 1999-02-05 SI SI9930743T patent/SI1056729T1/xx unknown
- 1999-02-05 ES ES99901083T patent/ES2237080T3/es not_active Expired - Lifetime
- 1999-02-05 SK SK1234-2000A patent/SK12342000A3/sk unknown
- 1999-02-05 HU HU0204418A patent/HUP0204418A3/hu not_active Application Discontinuation
- 1999-02-05 EA EA200000789A patent/EA003603B1/ru not_active IP Right Cessation
- 1999-02-05 KR KR10-2003-7012300A patent/KR20030083004A/ko not_active Ceased
- 1999-02-05 CA CA002321642A patent/CA2321642A1/en not_active Abandoned
- 1999-02-05 KR KR10-2003-7009644A patent/KR20030078886A/ko not_active Ceased
- 1999-02-05 JP JP2000533420A patent/JP2002504546A/ja active Pending
- 1999-02-05 CN CN99802628A patent/CN1289326A/zh active Pending
- 1999-02-05 KR KR10-2000-7009529A patent/KR100449600B1/ko not_active Expired - Fee Related
- 1999-02-05 TR TR2000/02480T patent/TR200002480T2/xx unknown
- 1999-02-05 EP EP04008203A patent/EP1454902A1/en not_active Withdrawn
- 1999-02-05 AU AU20706/99A patent/AU739403B2/en not_active Ceased
- 1999-02-05 HR HR20000550A patent/HRP20000550A2/hr not_active Application Discontinuation
- 1999-02-05 BR BR9908332-9A patent/BR9908332A/pt not_active IP Right Cessation
- 1999-02-05 US US09/367,731 patent/US6492401B1/en not_active Expired - Fee Related
- 1999-02-22 TW TW088102574A patent/TWI226329B/zh active
- 1999-02-22 GT GT199900022A patent/GT199900022A/es unknown
- 1999-02-23 PE PE1999000156A patent/PE20000334A1/es not_active Application Discontinuation
- 1999-02-24 TN TNTNSN99028A patent/TNSN99028A1/fr unknown
- 1999-02-24 DZ DZ990032A patent/DZ2729A1/xx active
- 1999-02-24 PA PA19998468401A patent/PA8468401A1/es unknown
- 1999-02-25 AP APAP/P/1999/001478A patent/AP9901478A0/en unknown
- 1999-02-25 AR ARP990100791A patent/AR015526A1/es unknown
- 1999-02-26 ZA ZA9901578A patent/ZA991578B/xx unknown
- 1999-03-01 CO CO99012526A patent/CO4980897A1/es unknown
2000
- 2000-06-27 IS IS5548A patent/IS5548A/is unknown
- 2000-08-18 OA OA1200000223A patent/OA11450A/en unknown
- 2000-08-22 NO NO20004192A patent/NO20004192D0/no not_active Application Discontinuation
- 2000-09-27 BG BG104803A patent/BG104803A/bg unknown
2002
- 2002-12-09 US US10/315,369 patent/US6974813B2/en not_active Expired - Fee Related
2004
- 2004-08-27 JP JP2004248129A patent/JP2005041879A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AU2070699A (en)	1999-09-15
HRP20000550A2 (en)	2001-02-28
PE20000334A1 (es)	2000-05-13
TNSN99028A1 (fr)	2005-11-10
NO20004192L (no)	2000-08-22
PA8468401A1 (es)	2000-09-29
YU46200A (sh)	2003-02-28
EP1056729A1 (en)	2000-12-06
PT1056729E (pt)	2005-04-29
HRP20010666A2 (en)	2001-10-31
NO20004192D0 (no)	2000-08-22
KR100407903B1 (ko)	2003-12-01
KR20030009548A (ko)	2003-01-29
GT199900022A (es)	2000-08-15
AR015526A1 (es)	2001-05-02
KR100449600B1 (ko)	2004-09-21
WO1999043663A1 (en)	1999-09-02
TR200002480T2 (tr)	2000-12-21
JP2005041879A (ja)	2005-02-17
EA003603B1 (ru)	2003-06-26
KR20030078886A (ko)	2003-10-08
BR9908332A (pt)	2000-11-07
ZA991578B (en)	2000-08-28
DE69922930T2 (de)	2005-12-29
HUP0204418A3 (en)	2003-10-28
SK12342000A3 (sk)	2001-03-12
TWI226329B (en)	2005-01-11
OA11450A (en)	2003-12-04
DK1056729T3 (da)	2005-04-11
EP1454902A1 (en)	2004-09-08
IL136588A0 (en)	2001-06-14
US20030149043A1 (en)	2003-08-07
CN1289326A (zh)	2001-03-28
DE69922930D1 (de)	2005-02-03
ATE286034T1 (de)	2005-01-15
CO4980897A1 (es)	2000-11-27
CA2321642A1 (en)	1999-09-02
KR20010041397A (ko)	2001-05-15
US6492401B1 (en)	2002-12-10
NZ504769A (en)	2005-04-29
IS5548A (is)	2000-06-27
ID25505A (id)	2000-10-05
AU739403B2 (en)	2001-10-11
PL342444A1 (en)	2001-06-04
SI1056729T1 (en)	2005-04-30
HUP0204418A2 (hu)	2003-04-28
BG104803A (bg)	2001-05-31
EP1056729B1 (en)	2004-12-29
ES2237080T3 (es)	2005-07-16
JP2002504546A (ja)	2002-02-12
KR20030083004A (ko)	2003-10-23
EA200000789A1 (ru)	2001-02-26
AP9901478A0 (en)	1999-03-31
US6974813B2 (en)	2005-12-13

Publication	Publication Date	Title
DZ3052A1 (fr)	2004-03-27	Composés nouveaux inhibiteurs de métalloprotéases,procédé pour leur préparation et compositions pha rmaceutiques les contenant.
CY2537B1 (fr)	2006-06-28	Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2753A1 (fr)	2005-09-15	Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr)	2004-03-15	Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2465A1 (fr)	2003-01-18	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
DZ2360A1 (fr)	2002-12-28	Dérivés de pyrazole procédé pour leur préparation et compositions les contenant
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3016A1 (fr)	2004-03-20	Composés nouveaux inhibiteurs de réabsorption de monoamines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr)	2003-12-15	4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2440A1 (fr)	2003-01-11	Atropisomères de 3-aryl-4(3h)-quinazolinones procédé pour leur préparation et compositions les contenant.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3038A1 (fr)	2004-03-27	Modulateurs nouveaux des récepteurs de glucocorticoïdes, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2745A1 (fr)	2003-09-08	BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2358A1 (fr)	2002-12-28	Amides inhibiteurs de sécrétion de apo b/mtp procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26611A1 (fr)	2004-12-20	Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2581A1 (fr)	2003-02-22	Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2394A1 (fr)	2003-06-04	Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.